Company Description
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer.
The company’s lead radiotherapeutic drug candidate is REYOBIQ, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.
It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection.
It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio.
The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019.
Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
| Country | United States |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Marc Hedrick |
Contact Details
Address: 2710 Reed Road, Suite 160 Austin, Texas 77051 United States | |
| Phone | 737 255 7194 |
| Website | plustherapeutics.com |
Stock Details
| Ticker Symbol | PSTV |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001095981 |
| CUSIP Number | 72941H400 |
| ISIN Number | US72941H5090 |
| Employer ID | 33-0827593 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Marc H. Hedrick M.B.A., M.D. | President, Chief Executive Officer and Director |
| Dr. Michael Stanley Rosol Ph.D. | Chief Development Officer |
| Desiree Smith | Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 7, 2025 | 144 | Filing |
| May 2, 2025 | 8-K | Current Report |
| May 1, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 30, 2025 | 10-K/A | [Amend] Annual report |
| Apr 23, 2025 | S-3/A | [Amend] Registration statement under Securities Act of 1933 |
| Apr 18, 2025 | 424B3 | Prospectus |
| Apr 18, 2025 | 8-K | Current Report |
| Apr 11, 2025 | POS AM | Post-Effective amendments for registration statement |
| Apr 10, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 4, 2025 | S-3 | Registration statement under Securities Act of 1933 |